Should You Buy Vistra After an 11% 1-Day Jump on a $4.2 Billion DOE Loan? The Catch Most Investors Are Missing.

Impact · against what's priced in

The news regarding the DOE loan and Q2 EBITDA growth for Vistra is already reflected in the current stock price. These developments confirm existing expectations for growth capital expenditures and current 2026 guidance, providing no new catalyst to bridge the gap to the market's declined assumptions regarding long-term contracted revenue.

VST+0.00: Already priced in
The price assumes: The $4.5B-$5B in planned growth capital expenditures that currently suppress free cash flow.

Should You Buy Vistra After an 11% 1-Day Jump on a $4.2 Billion DOE Loan? The Catch Most Investors Are Missing.

What matters in this story

Here's How Microsoft's $175 Billion in Capital Expenditures Is Hurting Its Business

Should You Buy Vistra After an 11% 1-Day Jump on a $4.2 Billion DOE Loan? The Catch Most Investors Are Missing.

What matters in this story

Here's How Microsoft's $175 Billion in Capital Expenditures Is Hurting Its Business

How each ticker is affected

Track these names every morning.

Is Micron's Incredible Run About to End?

UnitedHealth: 3 Key Takeaways for Long-Term Investors

As Chip Stocks Sell Off, This Is the Flight-to-Safety Play I Would Choose

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Duolingo, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DUOL

Should You Buy Vistra After an 11% 1-Day Jump on a $4.2 Billion DOE Loan? The Catch Most Investors Are Missing.

What matters in this story

Next reads from the same story arc

Here's How Microsoft's $175 Billion in Capital Expenditures Is Hurting Its Business

Should You Buy Vistra After an 11% 1-Day Jump on a $4.2 Billion DOE Loan? The Catch Most Investors Are Missing.

What matters in this story

Next reads from the same story arc

Here's How Microsoft's $175 Billion in Capital Expenditures Is Hurting Its Business

How each ticker is affected

Track these names every morning.

Is Micron's Incredible Run About to End?

UnitedHealth: 3 Key Takeaways for Long-Term Investors

As Chip Stocks Sell Off, This Is the Flight-to-Safety Play I Would Choose

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Duolingo, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DUOL